Global Anaplastic Lymphoma Kinase Non Small Cell Lung Cancer Market - Epidemiology Forecast to 2030 - ResearchAndMarkets.com

DUBLIN--()--The "Anaplastic Lymphoma Kinase Non Small Cell Lung Cancer (ALK-NSCLC) - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the disease, historical and forecasted ALK NSCLCepidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

There are mainly two types of lung cancer small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC can be defined as any type of epithelial lung cancer other than SCLC. It is mainly subcategorized into adenocarcinomas, squamous cell carcinomas, large cell carcinomas and several other types that occur less frequently include adenosquamous carcinomas, and sarcomatoid carcinomas. In these subtypes adenocarcinoma accounts for highest number of cases, i.e., approximately 47% followed by Squamous Cell Carcinoma and Large Cell Carcinoma.

There are several genetic mutations identified to play a major role in the progression of this indication. Mutations in EGFR, KRAS, and ALK are mutually exclusive in patients with NSCLC, and the presence of one mutation instead of another can influence response to targeted therapy. There are several mutations associated with NSCLC but the most common are EGFR, KRAS, ROS-1, BRAF, C-Met, PD-L1 expression and others. Among all the mutations ALK mutation accounted for approximately 4% of the total cases of NSCLC.

ALK-positive mutation was discovered in 2007. ALK-positive lung cancers harbor a gene rearrangement referred to as the EML4-ALK fusion gene, compose a subset of tumors for which medical treatment has expanded rapidly (along with survival) in the past few years. An ALK mutation is diagnosed by molecular profiling of a sample of the tumor. It's important in doing this testing that an adequate supply of tissue from either a lung biopsy or lung cancer surgery is obtained. Researchers are also looking at ways to determine if an ALK mutation is present before genetic testing is done, or could substitute for genetic testing.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Anaplastic lymphoma kinase-Non Small Cell Lung Cancer?
  • What are the key findings pertaining to the Anaplastic lymphoma kinase-Non-Small Cell Lung Cancer epidemiology across the 7MM and which country will have the highest number of patients during the study period (2017-2030)?
  • What would be the total number of patients of Anaplastic lymphoma kinase-Non-Small Cell Lung Cancer across the 7MM during the study period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the study period (2017-2030)?
  • At what CAGR the patient population is expected to grow in the 7MM during the study period (2017-2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of Anaplastic lymphoma kinase-Non-Small Cell Lung Cancer?

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global Anaplastic lymphoma kinase-Non Small Cell Lung Cancer market
  • Quantify patient populations in the global Anaplastic lymphoma kinase-Non Small Cell Lung Cancer market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Anaplastic lymphoma kinase-Non Small Cell Lung Cancer therapeutics in each of the markets covered
  • Understand the magnitude of Anaplastic lymphoma kinase-Non Small Cell Lung Cancer population by its severity
  • The Anaplastic lymphoma kinase-Non Small Cell Lung Cancer epidemiology report and model were written and developed by Masters and PhD level epidemiologists
  • The Anaplastic lymphoma kinase-Non Small Cell Lung Cancer Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Topics Covered:

1. Key Insights

2. Executive Summary of ALK-NSCLC

3. SWOT Analysis of ALK-NSCLC

4. ALK-NSCLC: Market Overview at a Glance

4.1. Total Incidence Share (%) Distribution of NSCLC in 2017: By Country

4.2. Total Incidence Share (%) Distribution of NSCLC in 2030: By Country

5. ALK-Non-small Cell Lung Cancer (NSCLC): Disease Background and Overview

5.1. Introduction

5.1.1. Cellular Classification of NSCLC

5.1.2. Signs and Symptoms of NSCLC

5.1.3. Risk Factors of Lung Cancer

5.1.4. Causes of NSCLC

5.1.5. Disease Biology: NSCLC

6. Diagnosis of NSCLC

6.1. Diagnostic Algorithm for NSCLC

6.2. Stages of NSCLC

6.3. Staging System

7. Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.4. The United States Epidemiology

8. EU-5 Epidemiology

8.1. Germany

8.2. France

8.3. Italy

8.4. Spain

8.5. The United Kingdom

9. Japan Epidemiology

10. Appendix

11. Publisher Capabilities

12. Disclaimer

13. About the Publisher

For more information about this report visit https://www.researchandmarkets.com/r/ms4pqs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900